Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients
Launched by GADJAH MADA UNIVERSITY · Aug 27, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the safety and benefits of using a natural remedy called Awar-Awar leaf, which comes from the Ficus Septica plant, as an additional treatment for women with stage IV breast cancer who are already receiving chemotherapy. The researchers want to see if this leaf extract can help improve the treatment experience and outcomes for these patients.
To participate in the trial, women must be at least 18 years old and currently undergoing chemotherapy for specific types of breast cancer (luminal B or triple-negative). They should also be in good enough health to participate, meaning they can carry out daily activities with minimal assistance. Participants will need to complete questionnaires and follow the study guidelines. This trial is currently recruiting, so if you or someone you know fits the eligibility criteria and is interested, it could be an opportunity to contribute to important research in breast cancer treatment.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female, at least 18 years old
- • Welfare scale 0, 1, and 2 (ECOG - WHO)
- • Patients with stage IV breast cancer who have histopathological data according to the TNM Classification of Malignant Tumors (TNM) from American Joint Committee on Cancer (AJCC) 8th edition 2017
- • Patients who are willing to participate in the test and sign an informed consent
- • Patients who undergo breast cancer chemotherapy with luminal B sub-type or triple negative with anthracycline base
- • Patients who are willing and able to fill out a questionnaire
- • The patients who are willing and able to comply with the test protocols during the test
- Exclusion Criteria:
- • Unable to meet the test protocol
- • Patients with liver and kidney disorders
- • Patients with other diseases/disorders that are meaningful according to the investigators will be excluded from the test
- • Patients with cancer that has metastasized to the brain
- • Pregnant women and breastfeeding mothers
- • Patients with the ejection fraction smaller-than or equal to 55%
About Gadjah Mada University
Gadjah Mada University, a prestigious institution located in Yogyakarta, Indonesia, is recognized for its commitment to advancing research and innovation in various fields, including health sciences. As a clinical trial sponsor, the university leverages its extensive academic expertise and state-of-the-art facilities to conduct rigorous clinical research aimed at enhancing medical knowledge and improving patient outcomes. With a focus on ethical standards and scientific integrity, Gadjah Mada University collaborates with healthcare professionals and researchers to ensure that its clinical trials contribute valuable insights to the medical community and support the development of effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Semarang, Jawa Tengah, Indonesia
Patients applied
Trial Officials
dr. Santosa, Ph.D
Principal Investigator
Dr. Kariadi General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials